1887

Abstract

Given the limited number of candidaemia studies in Iran, the profile of yeast species causing bloodstream infections (BSIs), especially in adults, remains limited. Although biochemical assays are widely used in developing countries, they produce erroneous results, especially for rare yeast species.

We aimed to assess the profile of yeast species causing BSIs and to compare the accuracy of the Vitek 2 system and 21-plex PCR.

Yeast blood isolates were retrospectively collected from patients recruited from two tertiary care training hospitals in Tehran from 2015 to 2017. Relevant clinical data were mined. Identification was performed by automated Vitek 2, 21-plex PCR and sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2).

In total, 137 yeast isolates were recovered from 107 patients. The overall all-cause 30-day mortality rate was 47.7 %. Fluconazole was the most widely used systemic antifungal. (58/137, 42.3 %), (30/137, 21.9 %), sensu stricto (23/137, 16.8 %), (10/137, 7.3 %) and () (4/137, 2.9 %) constituted almost 90 % of the isolates and 10 % of the species detected were rare yeast species (12/137; 8.7 %). The 21-plex PCR method correctly identified 97.1 % of the isolates, a higher percentage than the Vitek 2 showed (87.6 %).

was the main cause of yeast-derived fungaemia in this study. Future prospective studies are warranted to closely monitor the epidemiological landscape of yeast species causing BSIs in Iran. The superiority of 21-plex PCR over automated Vitek 2 indicates its potential clinical utility as an alternative identification tool use in developing countries.

Funding
This study was supported by the:
  • , National Natural Science Foundation of China, http://dx.doi.org/10.13039/501100001809, (Award 31770161)
  • , Tehran University of Medical Sciences , (Award 99-1-99-46391)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001189
2020-05-05
2020-06-02
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/5/712.html?itemId=/content/journal/jmm/10.1099/jmm.0.001189&mimeType=html&fmt=ahah

References

  1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309–317 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  2. Sellami A, Sellami H, Néji S, Makni F, Abbes S et al. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia. Mycopathologia 2011; 171:417–422 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  3. Meletiadis J, Arabatzis M, Bompola M, Tsiveriotis K, Hini S et al. Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. J Clin Microbiol 2011; 49:2722–2727 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  4. Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clinical Infectious Diseases 2019; 68:1791–1797 [CrossRef]
    [Google Scholar]
  5. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11:142–151 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  6. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018; 73:i4–i13 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  7. Ahangarkani F, Shokohi T, Rezai MS, Ilkit M, Mahmoodi Nesheli H et al. Epidemiological features of nosocomial candidaemia in neonates, infants and children: a multicentre study in Iran. Mycoses 2020; 63:382–394 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  8. Arastehfar A, Wickes BL, Ilkit M, Pincus DH, Daneshnia F et al. Identification of mycoses in developing countries. J Fungi 2019; 5:90 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  9. Arastehfar A, Fang W, Pan W, Lackner M, Liao W et al. Yeast panel multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagn Microbiol Infect Dis 2019; 93:112–119 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  10. Arastehfar A, Fang W, Al-Hatmi AMS, Afsarian MH, Daneshnia F et al. Unequivocal identification of an underestimated opportunistic yeast species, Cyberlindnera fabianii, and its close relatives using a dual-function PCR and literature review of published cases. Medical Mycology 2019; 57:833–840 [CrossRef]
    [Google Scholar]
  11. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A et al. Multidrug-Resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 2015; 53:1823–1830 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  12. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM et al. Candida auris: a review of the literature. Clin Microbiol Rev 2018; 31:e00029–00017 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  13. Durán-Valle MT, Sanz-Rodríguez N, Muñoz-Paraíso C, Almagro-Moltó M, Gómez-Garcés JL. Identification of clinical yeasts by Vitek MS system compared with API ID 32 C. Med Mycol 2014; 52:342–349 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  14. Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G et al. Evaluation of Vitek 2 and rapid yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 2007; 45:1343–1346 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  15. Keçeli SA, Dündar D, Tamer GS. Comparison of Vitek matrix-assisted laser desorption/ionization time-of-flight mass spectrometry versus conventional methods in Candida identification. Mycopathologia 2016; 181:67–73 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  16. Chindamporn A, Chakrabarti A, Li R, Sun P-L, Tan B-H et al. Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia fungal Working Group (AFWG) initiative. Medical Mycology 2018; 56:416–425 [CrossRef]
    [Google Scholar]
  17. Arastehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H et al. Comparison of 21-Plex PCR and API 20C aux, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-Plex PCR and API 20C aux as an alternative strategy for developing countries. Front Cell Infect Microbiol 2019; 9:21 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  18. Sadrossadati SZ, Ghahri M, Imani Fooladi AA, Sayyahfar S, Beyraghi S et al. Phenotypic and genotypic characterization of Candida species isolated from candideamia in Iran. Curr Med Mycol 2018; 4:14 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  19. Razzaghi R, Momen-Heravi M, Erami M, Nazeri M. Candidemia in patients with prolonged fever in Kashan, Iran. Curr Med Mycol 2016; 2:20 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  20. Ahmadi NA, Davodi L. Candidemia after cardiac surgery in Tehran, Iran: a retrospective analysis of 424 cases at two medical centers. Alexandria J Med 2018; 54:517–521 [CrossRef]
    [Google Scholar]
  21. Salehi M, Ghomi Z, Mirshahi R, Dehghan Manshadi SA, Rezahosseini O. Epidemiology and outcomes of candidemia in a referral center in Tehran. Caspian J Intern Med 2019; 10:73 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  22. Kafshdooz Jabari S, Chadeganipour M, Ghahri M, Mohammadi R. Etiologic agents of Candidemia in pediatric immunocompromised patients. Iranian Journal of Pediatric Hematology and Oncology 2016; 6:209–215
    [Google Scholar]
  23. Pincus DH. Microbial identification using the bioMérieux Vitek® 2 system. Encyclopedia of Rapid Microbiological Methods Bethesda, MD: Parenteral Drug Association; 2006 pp 1–32
    [Google Scholar]
  24. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol:chloroform. CSH Protoc 2006; 2006:pdb. prot4455 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  25. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara J-P et al. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 2006; 44:693–699 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  26. Mirhendi H, Charsizadeh A, Eshaghi H, Nikmanesh B, Arendrup MC. Species distribution and antifungal susceptibility profile of Candida isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran. Medical Mycology 2019; 26: [CrossRef]
    [Google Scholar]
  27. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014; 20 Suppl 6:5–10 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  28. Vaezi A, Fakhim H, Khodavaisy S, Alizadeh A, Nazeri M et al. Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis. J Mycol Med 2017; 27:146–152 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  29. Astvad KMT, Johansen HK, Røder BL, Rosenvinge FS, Knudsen JD et al. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. J Clin Microbiol 2018; 56:e01564–01517 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  30. Lindberg E, Hammarström H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci Rep 2019; 9:3838 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  31. Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R et al. Twenty-Two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 2015; 21:938–945 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  32. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two us metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One 2015; 10:e0120452 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  33. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother 2017; 72:1270–1108 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  34. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41:285–295 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  35. Khan Z, Ahmad S, Al-Sweih N, Mokaddas E, Al-Banwan K et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS One 2019; 14:e0216250 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  36. Guo F, Yang Y, Kang Y, Zang B, Cui W et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013; 68:1660–1668 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  37. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013; 8:e59373 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  38. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases Society of America. Clin Infect Dis 2016; 62:civ933–e50 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  39. Arastehfar A, Daneshnia F, Zomorodian K, Najafzadeh MJ, Khodavaisy S et al. Low level of antifungal resistance in Iranian isolates of Candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1 . Antimicrob Agents Chemother 2019; 63:e02503–02518 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  40. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014; 20:O245–O254 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  41. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014; 40:1303–1312 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  42. Doi AM, Pignatari ACC, Edmond MB, Marra AR, Camargo LFA et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian national surveillance program. PLoS One 2016; 11:e0146909 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  43. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33:1676–1681 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  44. Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated infection surveillance network (TRANSNET). Transpl Infect Dis 2016; 18:921–931 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  45. Chen P-Y, Chuang Y-C, Wu U-I, Sun H-Y, Wang J-T et al. Clonality of fluconazole-nonsusceptible Candida tropicalis in bloodstream infections, Taiwan, 2011–2017. Emerg Infect Dis 2019; 25:16681667 [CrossRef]
    [Google Scholar]
  46. Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh M-J et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol 2019; 41: [CrossRef][PubMed][PubMed]
    [Google Scholar]
  47. Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother 2015; 59:7715–7722 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  48. Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol 2014; 52:1830–1837 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  49. Reuter CWM, Morgan MA, Bange F-C, Gunzer F, Eder M et al. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis 2005; 41:1365–1366 [CrossRef][PubMed][PubMed]
    [Google Scholar]
  50. Sugita T, Takeo K, Ohkusu M, Virtudazo E, Takashima M et al. Fluconazole-Resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production. Microbiol Immunol 2004; 48:761–766 [CrossRef][PubMed][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001189
Loading
/content/journal/jmm/10.1099/jmm.0.001189
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error